Covidien endotracheal tube helps prevent pneumonia
This article was originally published in The Gray Sheet
Executive Summary
Covidien says its Mallinckrodt SealGuard Evac entdotracheal tube, launched Feb. 2 at the Society of Critical Care Medicine Congress in Nashville, is designed to reduce microaspiration of secretions into the lungs by 95% compared with products currently on the market with high-volume, low-pressure cuffs. The device also helps provide secretion drainage through an integrated suction lumen. Last fall, the company announced plans to target high-growth market segments in the respiratory care business, including devices to fight ventilator-associated pneumonia (1"The Gray Sheet" Sept. 15, 2008, p. 13). The product received 510(k) clearance on Oct. 2, 2008
You may also be interested in...
Covidien Aims To Breathe Life Into Respiratory Biz With Ventilation Pipeline
Covidien plans to reinvigorate its respiratory business by targeting higher-growth market segments, such as devices to combat ventilator-associated pneumonia, the company said during its Sept. 10 investor day in New York
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.